Modeling rett syndrome using human induced pluripotent stem cells

Tomoko Andoh-Noda, Michiko O. Inouye, Kunio Miyake, Takeo Kubota, Hideyuki Okano, Wado Akamatsu

研究成果: Article

2 引用 (Scopus)

抜粋

Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.

元の言語English
ページ(範囲)544-550
ページ数7
ジャーナルCNS and Neurological Disorders - Drug Targets
15
発行部数5
出版物ステータスPublished - 2016 5 1

    フィンガープリント

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

これを引用

Andoh-Noda, T., Inouye, M. O., Miyake, K., Kubota, T., Okano, H., & Akamatsu, W. (2016). Modeling rett syndrome using human induced pluripotent stem cells. CNS and Neurological Disorders - Drug Targets, 15(5), 544-550.